LONDON ( TheStreet) -- AstraZeneca ( AZN) said Wednesday the U.S. Food and Drug Administration has extended the time to complete its review of ticagrelor , the company's experimental blood thinner. AstraZeneca, the U.K. drugmaker, said the FDA extended its review by three months to Dec. 16. "AstraZeneca will continue to work closely with the FDA to support the review of the ticagrelor (new drug application)," the company said in a statement Wednesday. Ticagrelor, which goes under brand name Brilinta, is seen as a potential blockbuster drug for AstraZeneca. It's currently under regulatory review in the European Union, Canada, and Brazil. -- Written by Joseph Woelfel >To contact the writer of this article, click here: Joseph Woelfel >To submit a news tip, send an email to: firstname.lastname@example.org.